Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

Area of Science:

• Immunotherapy
• Hematologic Malignancies
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapies have advanced cancer treatment, but challenges remain for certain diseases.
• CAR-NK cell therapies offer a potential allogeneic, off-the-shelf alternative with promising early clinical data.
• Acute myeloid leukemia (AML) presents unique biological challenges for CAR-based immunotherapies compared to B-cell malignancies.

Purpose of the Study:

• To review the potential of CAR-NK cell therapies specifically for treating acute myeloid leukemia (AML).
• To evaluate the suitability of CAR-NK cells by examining the role of NK cells in AML biology and existing anti-leukemic activity.
• To assess AML target antigens, challenges, and the current development landscape for CAR-NK therapies.

Main Methods:

• Literature review of CAR T-cell and CAR-NK cell therapies in AML.
• Analysis of natural killer (NK) cell biology and function in the context of AML.
• Appraisal of potential AML target antigens and comparison with B-cell targets.
• Summary of current CAR-NK development in AML, including augmentation strategies.

Main Results:

• Natural killer (NK) cells play an established role in AML biology with demonstrated anti-leukemic activity via adoptive transfer.
• CAR-NK cell therapy development for AML is progressing, with ongoing research into suitable target antigens.
• Challenges in targeting AML with CAR-NK cells exist, necessitating strategies for pharmacological and genetic augmentation.

Conclusions:

• CAR-NK cell therapies possess innate potential for treating AML, leveraging NK cell's natural anti-leukemic functions.
• Despite progress, barriers remain for CAR-NK cell therapy in AML, requiring further research and development.
• CAR-NK cells represent a promising complementary immunotherapy approach for AML, distinct from CAR-T cell strategies.